NHS launches large GP-based blood test trial for earlier cancer detection
England is opening a large-scale blood test trial designed to help GPs detect cancer earlier in patients with abdominal symptoms. More than 20,000 NHS patients aged 45 and over will be invited to take part across at least 200 GP practices, where researchers will assess whether simple blood tests can identify signs of bowel, pancreatic, ovarian, prostate and other abdominal cancers before more serious symptoms emerge.
The study, called STRIDE-RCT, is being positioned as a test of whether blood-based cancer detection can function as a practical aid in routine primary care rather than as a stand-alone diagnostic answer. Patients visiting their GP with abdominal symptoms such as persistent bloating or discomfort will be offered participation, and the tests will be used alongside routine blood work and clinical judgement. A positive result may help direct urgent referral, but it does not confirm cancer on its own.
The scale matters because abdominal cancers are frequently detected late, when treatment options narrow and survival falls sharply. In bowel cancer alone, around 9 in 10 people diagnosed at stage 1 survive at least 5 years, compared with around 1 in 10 at stage 4. In that gap lies the central logic of the trial: earlier biological signal, earlier investigation, earlier treatment.
Multi-cancer detection in one blood sample
The trial will evaluate blood tests that look for signs of several cancers in a single sample and attempt to suggest where in the body the signal originates. The tests were developed by the University of Birmingham and rely on technologies that include artificial intelligence and protein measurement. In practice, most participants will have one or two tubes of blood drawn at their GP practice, an approach that is far less invasive than the imaging, endoscopy or specialist review that often follows vague abdominal complaints.
A single-sample approach is attractive because abdominal cancers often advertise themselves with symptoms that are common, nonspecific and easily mistaken for benign disease. Persistent bloating, discomfort, indigestion and pain can appear in routine primary care every day, yet the same symptoms can also accompany cancers of the pancreas, stomach, bowel or ovary. Blood-based detection is aimed at narrowing that diagnostic uncertainty by identifying molecular patterns that point toward malignant disease rather than waiting for more dramatic clinical deterioration.
A direct consequence of that uncertainty is already visible in referral patterns. Just 2% to 6% of urgent cancer referrals currently result in a diagnosis. If blood tests can help GPs separate low-risk presentations from patients who genuinely need urgent investigation, the NHS could reduce avoidable anxiety, conserve specialist capacity and move suspicious cases into the diagnostic pathway sooner.
Which cancers are included and why the setting matters
The trial covers a broad set of abdominal and related cancers: bowel, small bowel, stomach, oesophageal, pancreatic, liver, bile duct and gallbladder, ovarian, endometrial, kidney, bladder and prostate. That range reflects a shared clinical problem rather than a single disease category. Many of these cancers first present with symptoms that are vague, intermittent or attributed to much more common conditions, and the window for early intervention is often short.
Current referral systems in general practice depend heavily on symptom pattern, persistence and clinical suspicion. Even skilled clinicians can struggle when a patient’s symptoms do not fit a classic cancer presentation, especially in the early stages when tumors have not yet caused weight loss, jaundice, bleeding or marked obstruction. Blood tests that detect circulating markers could change the sequence of care by identifying high-risk patients before the disease announces itself more loudly.
The biology behind this strategy is straightforward. Tumors shed proteins, genetic material and other signals into the bloodstream, and modern analytic tools can search for those patterns at levels too subtle for ordinary testing. If those signals correlate with true cancer, the test could become a triage tool that improves the timing of imaging and specialist referral.
Evidence needed before routine rollout
The trial will compare how well these blood tests perform when used alongside GP judgement before any decision is made about broader NHS adoption. That caution is built into the design. Even a promising test can create harm if it generates false reassurance, unnecessary investigation or a flood of positives that outstrips diagnostic services. The study therefore has to answer a practical question: does the test improve real-world decision-making enough to justify use in routine primary care?
The public funding attached to the programme is substantial. The Office for Life Sciences, through the National Institute for Health and Care Research, is providing up to £8.49 million for the study, which will also span inner-city, rural, seaside and deprived communities. Including that range of settings is clinically important because abdominal cancers are not distributed evenly, and people in deprived areas are more likely to present as emergencies.
Professor Peter Johnson said the NHS is seeking a solution to the difficulty of early abdominal cancer detection, where symptoms can be mistaken for less serious conditions. Professor Aneel Bhangu described the twin problem facing GPs and surgeons: too many patients arrive after months of vague symptoms, while many urgent referrals ultimately do not have cancer. Dr Anisha Patel, speaking as both a GP and bowel cancer survivor, pointed to the way persistent symptoms can overlap with other illnesses and emphasized that patient concerns, follow-up and screening still need to remain central.
What a positive result can and cannot do
A positive result in STRIDE-RCT may help a GP decide whether urgent investigation is needed, but it cannot establish a cancer diagnosis by itself. That distinction is central in primary care, where the value of a test often lies in triage rather than certainty. A useful cancer blood test does not replace clinical examination, history-taking or symptom tracking; it adds another layer of evidence when the diagnosis is still uncertain.
Professor Lucy Chappell said the study will assess whether placing multi-cancer detection blood tests directly into routine GP consultations can support earlier diagnosis. Michelle Mitchell, from Cancer Research UK, called the trial an important step toward answering whether these tests can help identify people who need further investigation. Jodie Moffat of Bowel Cancer UK welcomed the study as a route to better bowel cancer diagnosis, while Pancreatic Cancer UK emphasized the need for new tools in a disease where vague symptoms often delay referral.
The most immediate clinical test is not whether the technology sounds impressive. It is whether it helps ordinary GP clinics find the right patients faster without overwhelming the system or missing disease in the process. This trial is built to provide that answer in a real NHS setting, and its value will depend on how well the blood tests perform in patients whose symptoms are common, mixed and easy to misread.